A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 [mavrilimumab] in Patients With Rheumatoid Arthritis.

Trial Profile

A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 [mavrilimumab] in Patients With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2012

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors MedImmune
  • Most Recent Events

    • 02 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 02 Nov 2011 Actual end date (October 2009) added as reported by ClinicalTrials.gov.
    • 25 May 2011 Results published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top